🇺🇸 FDA
GRAS · DSHEA dietary supplement · NDI for MK-7 cleared
Vitamin K2 · Menaquinone (MK-4 · MK-7)
Also known as: Menaquinone-7 · MK-7 · MK-4 · Menatetrenone
Mechanism of action
- Cofactor for γ-glutamyl carboxylase activating Gla-proteins
- Carboxylates osteocalcin (bone matrix incorporation of calcium)
- Carboxylates matrix Gla protein (inhibits vascular calcification)
Molecular + tissue targets
- Osteocalcin γ-carboxylation
- Matrix Gla protein
- Vascular calcification
Dosage range
90 μg/day NRV (men) · 90 μg/day (women); typical MK-7 supplement dose 90-200 μg/day. Geleijnse 2004 PMID 15514282 J Nutr Rotterdam Study cohort (n = 4,807) reported the highest tertile of dietary menaquinone intake associated with lower CHD mortality (RR 0.43, 95% CI 0.24-0.77) and severe aortic calcification (OR 0.48). Rønn 2021 PMID 33030563 Osteoporos Int 3-year RCT (n = 142 postmenopausal women with osteopenia, 375 μg MK-7/day + D3 + Ca) found osteocalcin carboxylation improved but bone mineral density and microarchitecture did not differ vs. placebo — honest mixed signal
Safety notes
Contraindicated in patients on vitamin K antagonist therapy (warfarin); inform clinician before starting MK-7 if on anticoagulants; otherwise excellent safety profile within typical supplement doses
Cross-market regulatory status
🇪🇺 EFSA
Authorized claims Reg 432/2012 bone maintenance + normal coagulation (vitamin K source threshold required); NRV 75 μg
🇧🇷 ANVISA
RDC 243/2018 dietary supplement · IN 28/2018 Anexo V alegação funcional verbatim: "A vitamina K auxilia na coagulação do sangue." Bone claim not separately authorized — vitamina K within bone-health stack must rely on Anexo V coagulação claim only
Authorized claims · verbatim (3)
Direct quotes from each jurisdiction's framework · never paraphrased · with framework reference and conditions of use.
🇪🇺 EFSA · 2 claims
Reg 432/2012
Vitamin K contributes to the maintenance of normal bones.
Conditions: Reg 1924/2006 art 10(2) + Annex: claim may only be used for food which is at least a "source of vitamin K" as referred to in the Annex to Reg 1924/2006
Authorized 2012
Reg 432/2012
Vitamin K contributes to normal blood clotting.
Conditions: Reg 1924/2006 art 10(2) + Annex: claim may only be used for food which is at least a "source of vitamin K" as referred to in the Annex to Reg 1924/2006
Authorized 2012
🇧🇷 ANVISA · 1 claim
IN 28/2018 Anexo V alegação funcional
A vitamina K auxilia na coagulação do sangue.
Conditions: IN 28/2018 Anexo V: alegação restrita a suplementos cujo aporte diário do nutriente atenda à quantidade mínima do Anexo II
Authorized 2018
Common use cases
- bone health framework
- arterial calcification mitigation adjunct
- maintenance of normal blood coagulation when K1 intake low
Cross-reference
Health goals: joint bone heart health menopause support longevity stack
Lifestyles: senior 60 plus menopause
Full dossier: /ingredients/vitamin-k2/
Machine-readable JSON: /api/nc/vitamin-k2.json